SIGA TECHNOLOGIES INC

Company Overview

SIGA Technologies is a commercial-stage specialty pharmaceutical company focused on medical countermeasures for orthopoxviruses. Its sole marketed product is TPOXX (tecovirimat) in oral and IV formulations, sold primarily to U.S. government agencies (notably BARDA and DoD) and select foreign governments under a large 19C BARDA procurement contract that drives most revenue and backlog. SIGA runs an asset‑light model, outsourcing all manufacturing to CMOs, conducts targeted R&D to support label expansions (a Supplemental NDA for smallpox PEP is targeted), and depends on a concentrated patent portfolio and government contracting relationships. Key operational characteristics are lumpy, timing‑sensitive government deliveries, margin pressure on IV product, and a small staff (about 46 FTEs).

Executive Compensation Practices

Given SIGA’s drug‑manufacturer / healthcare profile and concentrated government‑contract revenue, executive pay is likely tied heavily to contract execution and regulatory milestones rather than broad commercial sales metrics typical of large pharma. Expect incentive structures that weight (a) successful BARDA/DoD deliveries and exercised options, (b) achievement of regulatory goals (e.g., Supplemental NDA, labeling wins), (c) cash‑flow and liquidity management, and (d) margin improvements on IV product—alongside standard base salary and benefits. As a small, asset‑light company, SIGA is also likely to use equity (options/RSUs) and milestone bonuses to retain and align a compact executive team, which helps conserve cash while rewarding long‑term value tied to patent life and government contracts. Recent disclosures (new executive hires and a special dividend) indicate the company has been adjusting SG&A and may include retention/sign‑on arrangements and time‑ or performance‑vested equity.

Insider Trading Considerations

Material nonpublic events for SIGA include BARDA option exercises/delivery schedules, recognition or catch‑up adjustments under ASC 606, regulatory filings and trial outcomes (Supplemental NDA, mpox/PEP trial data, EMA/MHRA activity), IV margin developments, and dividend declarations—any of which can move the stock and create heightened insider information risk. As a Section 16 reporting company in the Healthcare / Drug Manufacturers industry, insiders must timely file Form 4s (two business days) and are subject to short‑swing profit rules; many executives at similarly situated firms use 10b5‑1 plans or blackout windows tied to reporting/contract delivery cycles to manage trading risk. The small leadership team and concentrated insider holdings mean option exercises or RSU vesting can lead to sizeable Form 4 activity; traders should watch for clustered sales following vesting, post‑BARDA announcements, and around quarterly reports where ASC 606 estimates produce catch‑up revenue. Finally, federal contracting status can bring additional internal trading policies and predictable blackout periods around major contract deliveries or procurements.